未登录.png)
分享.png)
收藏分享 收藏 Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study依匹木单抗联合纳武利尤单抗，联合或不联合化疗，根据基线肿瘤大小评估其疗效：一项多中心回顾性研究
Tanaka, Hisashi; Makiguchi, Tomonori; Tozuka, Takehiro; Kawashima, Yosuke; Oba, Tomohiro; Tsugitomi, Ryosuke; Koyama, Junji; Tambo, Yuichi; Ogusu, Shinsuke; Saiki, Masafumi; Gyotoku, Hiroshi; Hasegawa, Tsukasa; Miyauchi, Eisaku; Sonoda, Tomoaki; Saito, Ryota; Nakatomi, Katsumi; Sakatani, Toshio; Kudo, Keita; Tsuchiya-Kawano, Yuko; Nishio, Makoto 分享 收藏 Timing and Risk Factors for Hyperglycemia Associated With Anamorelin Administration阿那莫林给药相关高血糖的发病时间及危险因素Amakawa, Yoshihiro; Kobayashi, Kazuo; Nonomiya, Yuma; Shimizu, Hisanori; Kawakami, Kazuyoshi; Yokokawa, Takashi; Sasahira, Naoki; Ozaka, Masato; Takeda, Tsuyoshi; Yamaguchi, Kensei; Takahari, Daisuke; Nishio, Makoto; Ariyasu, Ryo; Kitazawa, Toru; Yamaguchi, Masakazu 分享 收藏 Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2J-TAIL-2研究中接受阿替利珠单抗联合疗法治疗的肺癌患者血浆蛋白质组学分析用于生物标志物发现Goto, Yasushi; Nishio, Makoto; Ohashi, Kadoaki; Osoegawa, Atsushi; Kikuchi, Eiki; Kimura, Hideharu; Shimizu, Junichi; Miyauchi, Eisaku; Yoshioka, Hiroshige; Yoshino, Ichiro; Misumi, Toshihiro; Watanabe, Yasutaka; Katakami, Nobuyuki; Kisohara, Akira; Yamaguchi, Masafumi; Kuroki, Hirotaka; Sugimoto, Masamichi; Ashimura, Hisao; Tanaka, Misa; Gemma, Akihiko 分享 收藏 分享 收藏 分享 收藏 Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with ALK-positive non-small cell lung cancerALINA研究结果的大众语言摘要：alectinib与化疗相比，在ALK阳性非小细胞肺癌患者术后的应用Wu, Yi-Long; Dziadziuszko, Rafal; Ahn, Jin Seok; Barlesi, Fabrice; Nishio, Makoto; Lee, Dae Ho; Lee, Jong-Seok; Zhong, Wenzhao; Horinouchi, Hidehito; Mao, Weimin; Hochmair, Maximilian; De Marinis, Filippo; Migliorino, Maria Rita; Bondarenko, Igor; Lu, Shun; Wang, Qun; Lohmann, Tania Ochi; Xu, Tingting; Cardona, Andres; Hiles, Laura; Noe, Johannes; Solomon, Benjamin J. 分享 收藏 Atezolizumab plus Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2)阿特珠单抗联合化疗治疗日本临床实践中晚期非小细胞肺癌（J-TAIL-2）Yoshioka, Hiroshige; Nishio, Makoto; Ohashi, Kadoaki; Osoegawa, Atsushi; Kikuchi, Eiki; Kimura, Hideharu; Goto, Yasushi; Shimizu, Junichi; Miyauchi, Eisaku; Yoshino, Ichiro; Misumi, Toshihiro; Watanabe, Yasutaka; Hata, Akito; Kisohara, Akira; Kuyama, Shoichi; Yamaguchi, Masafumi; Miwa, Asako; Iwasawa, Shunichiro; Tanaka, Misa; Gemma, Akihiko 分享 收藏 分享 收藏 The first case of GOLGA5-RET fusion-positive malignant spindle cell sarcoma of the head and neck responsive to selpercatinib头颈部GOLGA5-RET融合阳性恶性梭形细胞肉瘤对selpercatinib有反应的首例病例。Nakao, Takehiro; Fukuda, Naoki; Wang, Xiaofei; Oki, Ryosuke; Urasaki, Tetsuya; Nakano, Kenji; Ono, Makiko; Tomomatsu, Junichi; Ariyasu, Ryo; Sato, Yukiko; Fukada, Ippei; Sasaki, Toru; Takeuchi, Kengo; Nishio, Makoto; Miura, Yuji; Takahashi, Shunji 分享 收藏 RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLCRELAY研究：雷莫芦单抗联合厄洛替尼在老年日本患者中针对转移性EGFR突变非小细胞肺癌的安全性与有效性Nishino, Kazumi; Seto, Takashi; Nishio, Makoto; Nishio, Kazuto; Kasahara, Kazuo; Satouchi, Miyako; Yoh, Kiyotaka; Hayashi, Hidetoshi; Enatsu, Sotaro; Matsui, Tomoko; Varughese, Sunoj Chacko; Visseren-Grul, Carla; Nakagawa, Kazuhiko 分享 收藏 分享 收藏 Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens免疫相关不良事件严重程度对接受免疫检查点抑制剂治疗的晚期非小细胞肺癌患者总生存期的影响，重点关注联合方案。Sugai, Mayu; Amino, Yoshiaki; Fujishima, Shunsuke; Nibuya, Kyujiro; Iso, Hirokazu; Ito, Masahiro; Tsugitomi, Ryosuke; Ariyasu, Ryo; Uchibori, Ken; Yanagitani, Noriko; Nishio, Makoto 分享 收藏 分享 收藏 First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial一线纳武利尤单抗联合铂类化疗和贝伐珠单抗治疗晚期非鳞非小细胞肺癌：TASUKI-52 III期随机试验3年随访Lee, Ki Hyeong; Lee, Jong-Seok; Sugawara, Shunichi; Kang, Jin Hyoung; Kim, Hye Ryun; Inui, Naoki; Hida, Toyoaki; Yoshida, Tatsuya; Tanaka, Hiroshi; Yang, Cheng-Ta; Inoue, Takako; Nishio, Makoto; Ohe, Yuichiro; Tamura, Tomohide; Yamamoto, Nobuyuki; Yu, Chong-Jen; Akamatsu, Hiroaki; Takahashi, Shigeru 分享 收藏 Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset拉姆昔利单抗联合厄洛替尼对比安慰剂联合厄洛替尼，用于未治EGFR突变型转移性非小细胞肺癌患者的最终生存结局：RELAY日本亚组Nishio, Makoto; Seto, Takashi; Reck, Martin; Garon, Edward B.; Nishio, Kazuto; Kasahara, Kazuo; Nishino, Kazumi; Satouchi, Miyako; Yoh, Kiyotaka; Hayashi, Hidetoshi; Sakai, Kazuko; Enatsu, Sotaro; Frimodt-Moller, Bente; Matsui, Tomoko; Varughese, Sunoj Chacko; Carlsen, Michelle; Visseren-Grul, Carla; Nakagawa, Kazuhiko 分享 收藏 Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49%): TOPGAN2023-01Tanaka, Hisashi; Makiguchi, Tomonori; Tozuka, Takehiro; Kawashima, Yosuke; Oba, Tomohiro; Tsugitomi, Ryosuke; Koyama, Junji; Tambo, Yuichi; Ogusu, Shinsuke; Saiki, Masafumi; Gyotoku, Hiroshi; Hasegawa, Tsukasa; Miyauchi, Eisaku; Sonoda, Tomoaki; Saito, Ryota; Nakatomi, Katsumi; Sakatani, Toshio; Kudo, Keita; Tsuchiya-Kawano, Yuko; Nishio, Makoto 分享 收藏 Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer靶向ErbB和tankyrase1/2可防止ALK阳性肺癌中耐药持续细胞的出现Fujimura, Takaaki; Furugaki, Koh; Mizuta, Hayato; Muraoka, Satoshi; Nishio, Makoto; Adachi, Jun; Uchibori, Ken; Miyauchi, Eisaku; Hayashi, Hidetoshi; Katayama, Ryohei; Yoshiura, Shigeki 分享 收藏 MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancerWei, Xinzhao; Uchibori, Ken; Kondo, Nobuyuki; Utsumi, Takahiro; Takemoto, Ai; Koike, Sumie; Takagi, Satoshi; Yanagitani, Noriko; Nishio, Makoto; Katayama, Ryohei 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
